Heng_mRCC v.1
Provides a prognostic assessment of overall survival in mRCC (metastatic renal cell carcinoma) patients treated with VEGF (vascular endothelial growth factor)–targeted therapy.
Provides a prognostic assessment of overall survival in mRCC (metastatic renal cell carcinoma) patients treated with VEGF (vascular endothelial growth factor)–targeted therapy.
Helps to roughly stratify patients with mRCC into 3 survival prognostic groups. No validated scroing systems available for the prediciton of mRCC survival but there are three survival groups with associated median survival: Score interpretation: Score Prognosis Median Survival ≤1 Favorable 43.2 months 2 Intermediate 22.5 months ≥3 Poor 7.8 months
Must be used with sound clinical judgment as validation of the tool is still to be completed.
Ref. 1: Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C,McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. JCO Dec 1, 2009:5794-5799; published online on October 13, 2009.
OBSERVATION.heng_score_for_metastatic_rcc_prognosis.v1, OBSERVATION.karnofsky_performance_status_scale.v1, OBSERVATION.lab_test-full_blood_count.v1, OBSERVATION.lab_test_serum_calcium.v1, EVALUATION.heng_score_for_mrcc_assessment.v1
